Results

1–10 of 43 results for nAMD

Expert Panel: Faricimab and Aflibercept 8 mg in AMD
John T. Thompson, MD
Andrew A. Moshfeghi, MD, MBA, FASRS
Manjot K Gill, MD, FASRS
Christina Y Weng, MD, MBA, FASRS
Ferhina S Ali, MD, MPH
Ian Pearce, MB ChB BSc FRCOPHTH
Annual Meeting Talks
2024
Safety and Efficacy of Switching to Biosimilar Ranibizumab in Eyes Initially Treated With Reference Ranibizumab for nAMD, DME, or RVO
Nikhil K Bommakanti, MD
Annual Meeting Talks
2024
Durability of Combination Therapy of Sozinibercept, an Anti-VEGF-C/D 'Trap' With Ranibizumab in nAMD or Aflibercept in DME
Nathan C. Steinle, MD
Annual Meeting Talks
2024
Subretinal Aflibercept vs Ranibizumab vs Bevacizumab in the Context of PPV: Pneumatic Displacement With Subretinal Air and tPA in Naïve Submacular Hemorrhage Due to nAMD
Matias Iglicki, MD
Annual Meeting Talks
2024
Pigment Epithelial Detachment Outcomes With Faricimab vs Aflibercept in Patients With nAMD: Results From TENAYA/LUCERNE
Aude Ambresin, MD, PD
Annual Meeting Talks
2024
PULSAR Extension: Clinical Improvements Sustained Over 156 Weeks With Aflibercept 8 mg in Patients With Neovascular Age-Related Macular Degeneration
David T.W. Wong, MD, FRCS(C), FASRS
Updates from the Field
2025
1-Year Results of a Phase 2 Pharmacodynamic Study: Subretinal Delivery of Investigational Gene Therapy ABBV-RGX-314 for Neovascular AMD
Robert L. Avery, MD
Updates from the Field
2025
PRISM Phase 2b Clinical Trial Evaluating Intravitreal 4D-150 in Adults With Neovascular Age-Related Macular Degeneration: 52-Week Results
John A. Wells, MD, FACS
Updates from the Field
2025
Baseline Factors Associated With 1-Year Outcomes in Phase III Comparison of SB11 (Approved Ranibizumab Biosimilar) With Reference Ranibizumab in nAMD
Neil M. Bressler, MD
Annual Meeting Talks
2022
ADVM-022 Intravitreal Gene Therapy for Neovascular AMD: Phase 1 OPTIC Trial Update
Dante Joseph Pieramici, MD
Annual Meeting Talks
2022